Physician profile
Jorge Antonio Tirado Gutierrez
NPI 1669630968
$31,996.92
in general payments reported to CMS, 2019-2025
17 companies · $18K in 2025
The $18K reported for 2025 was more than what 92% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $313 · 2020: $3,091 · 2021: $841 · 2022: $4,481 · 2023: $1,302 · 2024: $3,938 · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $17K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,250 · Food and Beverage: $2,361 · Travel and Lodging: $1,110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $16,550.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,250.00 |
| Food and Beverage | $2,360.73 |
| Travel and Lodging | $1,110.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recor Medical INC | $14,509.64 | 2024-2025 | Paradise Ultrasound Renal Denervation System, Paradise Renal Denervation System |
| Boston Scientific Corporation | $7,239.38 | 2020-2025 | Avvigo Guidance System, Opticross, Watchman Flx |
| Biotronik INC. | $3,800.00 | 2025 | Pk Papyrus, Orsiro Mission |
| Janssen Global Services, LLC | $3,030.00 | 2022 | |
| Janssen Pharmaceuticals, INC | $2,025.00 | 2020 | |
| Medicure Pharma INC. | $700.00 | 2020-2021 | |
| Bard Peripheral Vascular, INC. | $207.03 | 2019-2021 | |
| Cardiovascular Systems INC. | $174.90 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.19 | 2019 | |
| Abbott Laboratories | $57.13 | 2024 | Optis, Esprit |
| Novartis Pharmaceuticals Corporation | $48.92 | 2025 | |
| Medtronic, INC. | $48.27 | 2024 | Symplicity G3 |
| Irhythm Technologies, INC. | $19.37 | 2024 | Zio Xt Patch, Zio Monitor |
| Terumo Medical Corporation | $18.15 | 2022 | |
| Pfizer INC. | $16.19 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $14.75 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Gutierrez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.